382 related articles for article (PubMed ID: 24483346)
21. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.
Manasanch EE; Berrios D; Fountain E; Claussen CM; Chuang T; Kaufman G; Amini B; Bashir Q; Nieto Y; Qazilbash M; Patel K; Thomas SK; Weber DM; Berkova Z; Toruner G; Lin P; Feng L; Lee HC; Orlowski RZ; Kunacheewa C
Br J Haematol; 2021 Feb; 192(4):e115-e120. PubMed ID: 33486754
[No Abstract] [Full Text] [Related]
22. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma.
Zanwar S; Kumar S
Leuk Lymphoma; 2021 Dec; 62(13):3087-3097. PubMed ID: 34304677
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and risk stratification in multiple myeloma.
van de Donk NW; Sonneveld P
Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
[TBL] [Abstract][Full Text] [Related]
24. Multiple myeloma: diagnosis and treatment.
Rajkumar SV; Kyle RA
Mayo Clin Proc; 2005 Oct; 80(10):1371-82. PubMed ID: 16212152
[TBL] [Abstract][Full Text] [Related]
25. High-risk Multiple Myeloma: Definition and Management.
Joseph NS; Gentili S; Kaufman JL; Lonial S; Nooka AK
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S80-S87. PubMed ID: 28760306
[TBL] [Abstract][Full Text] [Related]
26. [The multiple myeloma--current view and perspectives].
Knop S
Med Monatsschr Pharm; 2014 Mar; 37(3):84-92; quiz 93-4. PubMed ID: 24741848
[TBL] [Abstract][Full Text] [Related]
27. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
28. Investigative tools for diagnosis and management.
Munshi NC
Hematology Am Soc Hematol Educ Program; 2008; ():298-305. PubMed ID: 19074100
[TBL] [Abstract][Full Text] [Related]
29. Advances in understanding prognosis in myeloma.
Smith D; Yong K
Br J Haematol; 2016 Nov; 175(3):367-380. PubMed ID: 27604166
[TBL] [Abstract][Full Text] [Related]
30. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.
Agnelli L; Tassone P; Neri A
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S55-68. PubMed ID: 23614397
[TBL] [Abstract][Full Text] [Related]
31. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
32. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
Stewart AK; Fonseca R
J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
[TBL] [Abstract][Full Text] [Related]
34. Multiple myeloma: is it time for biomarker-driven therapy?
Bhutani M; Landgren O; Usmani SZ
Am Soc Clin Oncol Educ Book; 2015; ():e493-503. PubMed ID: 25993214
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
36. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Munshi NC; Anderson KC; Bergsagel PL; Shaughnessy J; Palumbo A; Durie B; Fonseca R; Stewart AK; Harousseau JL; Dimopoulos M; Jagannath S; Hajek R; Sezer O; Kyle R; Sonneveld P; Cavo M; Rajkumar SV; San Miguel J; Crowley J; Avet-Loiseau H;
Blood; 2011 May; 117(18):4696-700. PubMed ID: 21292777
[TBL] [Abstract][Full Text] [Related]
37. Initial treatment of transplant-eligible patients in multiple myeloma.
Rosiñol L; Kumar S; Moreau P; Cavo M
Expert Rev Hematol; 2014 Feb; 7(1):43-53. PubMed ID: 24392968
[TBL] [Abstract][Full Text] [Related]
38. Toward personalized treatment in multiple myeloma based on molecular characteristics.
Pawlyn C; Davies FE
Blood; 2019 Feb; 133(7):660-675. PubMed ID: 30587529
[TBL] [Abstract][Full Text] [Related]
39. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies F; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan G
Leukemia; 2019 Jan; 33(1):159-170. PubMed ID: 29967379
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the management of multiple myeloma.
Kumar L; Verma R; Radhakrishnan VR
Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
